American BriVision (ABVC) Improves Working Capital and Reduce Debt.
American BriVision Announces Two Financial Transactions to Improve Working Capital and Reduce Debt
FREMONT, CA, April 13, 2020...
FDA Authorizes Athersys (ATHX) to Initiate a Pivotal Clinical Trial!
FDA Authorizes Athersys to Initiate a Pivotal Clinical Trial Evaluating MultiStem® Cell Therapy in Patients With COVID-19 Induced Acute Respiratory Distress Syndrome.
Exosomes, Extracellular Vesicles, and the CoronaVirus.
Uploading a Series of Articles on Extracellular Vesicles, Including Potential Effects on the CoronaVirus and ARDS.
Article #1:...
Adding Corbis Pharma (CRBP) $5.55 to Watch List.
Running Clinical Trials Full Steam With $46 Million Banked in Late February.
Not thinly, but lightly traded. Ready,...
Boo Ya. Brokerage Sets $12 Price Target for Athersys (ATHX) $2.96.
A major Wall Street firm that specializes in Bio and Medtech Companies has a $12 price target out on Athersys from one...
Adding American BriVision (ABVC) $2.00 to Watch List.
New client and an incubator, studying now. Thinly, thinly traded. We like what we've read so far about their vitreous substitute (eyeball...
Immunomedics (IMMU) up 100% Today or $2 Billion in Value & Stand Down VIII:
Bear Comments from Roubini, Jim Chanos, Jim Rogers and James A. Kostohryz
Don't Be That Guy in Denial!
Citius (CTXR) and Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19
Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19
New Report: Citius (CTXR) Trades 13 Million Shares on CoronaVirus and Candida Auris News.
Announces Mino-lok® Erdicates the Deadly and Untreatable C. Auris Bacteria.Announces License of Treatment for CoronaVirus Respiratory Failure.
OMNIQ (OMQS) Corp. Acquires Eyepax Parking Assets.
OMNIQ Corp. Acquires Eyepax USA's Intellectual Property and Technology to Establish Leadership in Multibillion Dollar Automated Parking Solutions Market
Latest article
Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.
Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.
CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...
GeoVax (GOVX) Launches Vaccine Manufacturing System.
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
Manufacturing Process for Phase 3 and Commercial Production...
